Journey Medical (Journey Medical) Debt-to-Revenue : 0.28 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Journey Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.08 Mil. Journey Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.68 Mil. Journey Medical's annualized Revenue for the quarter that ended in Mar. 2024 was $52.12 Mil. Journey Medical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.28.

Journey Medical Debt-to-Revenue Historical Data

The historical data trend for Journey Medical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Debt-to-Revenue Chart

Journey Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

0.15

0.12

0.01

0.31

0.19

Journey Medical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial												0.47	0.15	-	0.24	0.28

Competitive Comparison of Journey Medical's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Journey Medical's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Journey Medical's Debt-to-Revenue falls into.

Journey Medical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Journey Medical's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.099	+	14.631)	/	79.181
	=	0.19

Journey Medical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.084	+	14.684)	/	52.12
	=	0.28

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Journey Medical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Journey Medical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Journey Medical (Journey Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258

Website

https://www.journeymedicalcorp.com

Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.

Executives

Jeffrey Paley	director	C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith	director	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Claude Maraoui	director, officer: President & CEO	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch	officer: Interim CFO	C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert	officer: Chief Financial Officer	4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135